ATE324884T1 - Verwendung von gamma-linolensäure oder dihomogammalinolensäure zur herstellung eines medikaments zur behandlung von huntington's chorea - Google Patents
Verwendung von gamma-linolensäure oder dihomogammalinolensäure zur herstellung eines medikaments zur behandlung von huntington's choreaInfo
- Publication number
- ATE324884T1 ATE324884T1 AT96307036T AT96307036T ATE324884T1 AT E324884 T1 ATE324884 T1 AT E324884T1 AT 96307036 T AT96307036 T AT 96307036T AT 96307036 T AT96307036 T AT 96307036T AT E324884 T1 ATE324884 T1 AT E324884T1
- Authority
- AT
- Austria
- Prior art keywords
- chorea
- huntington
- acid
- medication
- gamma
- Prior art date
Links
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 title abstract 3
- 208000023105 Huntington disease Diseases 0.000 title abstract 3
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 title 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 title 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 title 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 title 1
- 229960002733 gamolenic acid Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9519661.4A GB9519661D0 (en) | 1995-09-27 | 1995-09-27 | Fatty acid treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE324884T1 true ATE324884T1 (de) | 2006-06-15 |
Family
ID=10781324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96307036T ATE324884T1 (de) | 1995-09-27 | 1996-09-26 | Verwendung von gamma-linolensäure oder dihomogammalinolensäure zur herstellung eines medikaments zur behandlung von huntington's chorea |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5837731A (de) |
| EP (1) | EP0766961B1 (de) |
| AT (1) | ATE324884T1 (de) |
| AU (1) | AU709867B2 (de) |
| CA (1) | CA2186673C (de) |
| DE (1) | DE69636085T2 (de) |
| ES (1) | ES2259442T3 (de) |
| GB (1) | GB9519661D0 (de) |
| NZ (1) | NZ299464A (de) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1109543C (zh) * | 1996-10-11 | 2003-05-28 | 斯卡里斯塔有限公司 | 包括二十碳五烯酸和/或十八碳四烯酸的药物制剂 |
| US6652866B1 (en) * | 1997-10-14 | 2003-11-25 | David W. Hertha | Method for treating diseases of fungal, yeast, and prion protein etiology |
| US7138431B1 (en) * | 1998-02-23 | 2006-11-21 | Wake Forest University | Dietary control of arachidonic acid metabolism |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| US7098352B2 (en) * | 2001-11-16 | 2006-08-29 | Virtus Nutrition Llc | Calcium salt saponification of polyunsaturated oils |
| GB0311081D0 (en) | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
| CA2436650A1 (en) * | 2003-08-06 | 2005-02-06 | Naturia Inc. | Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses |
| FI20060154A7 (fi) | 2003-08-18 | 2006-05-11 | Btg Int Ltd | Neurogeneratiivisten tilojen hoito |
| CA2569230C (en) * | 2004-04-30 | 2014-12-02 | Nutriscience Technology, Inc. | Polyunsaturated fatty acid monovalent and divalent metal salt synthesis |
| GB0504362D0 (en) | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
| US8343753B2 (en) * | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| WO2010028067A1 (en) | 2008-09-02 | 2010-03-11 | Amarin Corporation Plc | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| KR101383006B1 (ko) | 2009-02-10 | 2014-04-08 | 아마린 파마, 인크. | 고중성지방혈증 치료 방법 |
| PT3278665T (pt) | 2009-04-29 | 2020-11-19 | Amarin Pharmaceuticals Ie Ltd | Composição farmacêutica estável e métodos de utilização das mesmas |
| SG175390A1 (en) | 2009-04-29 | 2011-12-29 | Amarin Corp Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| CN106074486A (zh) | 2009-06-15 | 2016-11-09 | 阿马里纳药物爱尔兰有限公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法 |
| US20110071176A1 (en) | 2009-09-23 | 2011-03-24 | Amarin Pharma, Inc. | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| RU2606853C2 (ru) * | 2010-03-04 | 2017-01-10 | Амарин Фармасьютикалз Айрлэнд Лимитед (Апил) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ778131A (en) | 2010-11-29 | 2023-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| EP2775837A4 (de) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | Verfahren zur behandlung von hypertriglyceridämie |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| EP4338805B1 (de) | 2012-06-29 | 2025-06-04 | Amarin Pharmaceuticals Ireland Limited | Eicosapentaensäureethylester zur verwendung bei der verringerung des risikos eines nicht-fatalen herzinfarktes bei einer person in statin-therapie |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| KR20210110890A (ko) | 2018-09-24 | 2021-09-09 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
| US12427134B2 (en) | 2019-11-12 | 2025-09-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2164291C (en) * | 1993-06-09 | 2007-10-30 | David John Kyle | Methods and pharmaceutical compositions useful for treating neurological disorders |
-
1995
- 1995-09-27 GB GBGB9519661.4A patent/GB9519661D0/en active Pending
-
1996
- 1996-09-26 DE DE69636085T patent/DE69636085T2/de not_active Expired - Lifetime
- 1996-09-26 EP EP96307036A patent/EP0766961B1/de not_active Expired - Lifetime
- 1996-09-26 ES ES96307036T patent/ES2259442T3/es not_active Expired - Lifetime
- 1996-09-26 AU AU65868/96A patent/AU709867B2/en not_active Ceased
- 1996-09-26 AT AT96307036T patent/ATE324884T1/de not_active IP Right Cessation
- 1996-09-26 US US08/721,329 patent/US5837731A/en not_active Expired - Fee Related
- 1996-09-27 CA CA002186673A patent/CA2186673C/en not_active Expired - Fee Related
- 1996-09-27 NZ NZ299464A patent/NZ299464A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69636085T2 (de) | 2006-12-07 |
| US5837731A (en) | 1998-11-17 |
| EP0766961A1 (de) | 1997-04-09 |
| CA2186673C (en) | 2008-07-22 |
| DE69636085D1 (de) | 2006-06-08 |
| GB9519661D0 (en) | 1995-11-29 |
| EP0766961B1 (de) | 2006-05-03 |
| ES2259442T3 (es) | 2006-10-01 |
| CA2186673A1 (en) | 1997-03-28 |
| AU6586896A (en) | 1997-04-10 |
| AU709867B2 (en) | 1999-09-09 |
| NZ299464A (en) | 2000-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE324884T1 (de) | Verwendung von gamma-linolensäure oder dihomogammalinolensäure zur herstellung eines medikaments zur behandlung von huntington's chorea | |
| ATE267607T1 (de) | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten | |
| DE69636343D1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
| ATE231885T1 (de) | Verwendung von komplement-inhibitoren zur herstellung eines arzneimittels zur prophylaxe und therapie von entzündlichen darm- und hauterkrankungen sowie purpura | |
| ATE205389T1 (de) | Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma | |
| ATE266417T1 (de) | Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien | |
| SE9401406L (sv) | Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma | |
| ATE213411T1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
| ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
| ATE275948T1 (de) | Verwendung von adamantan derivaten zur herstellung eines medikaments zur glaukombehandlung | |
| DE3876877D1 (de) | Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus. | |
| ATE135577T1 (de) | Verwendung von buspiron zur herstellung eines pharmazeutischen präparats zur behandlung der alkoholsucht | |
| DE69526937D1 (de) | Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen | |
| DE69424777D1 (de) | 3,4-diarylchromane zur behandlung von dermatitis | |
| ATE137965T1 (de) | Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege | |
| ATE274349T1 (de) | Verwendung von fruktan zur herstellung eines arzneimittels zur vorbeugung und behandlung von dickdarmkrebs | |
| ATE172117T1 (de) | Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten | |
| ATE307203T1 (de) | Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma | |
| DE3850154D1 (de) | Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression. | |
| AU1870097A (en) | Use of a medicament and use of mixture of substances to produce a medicament | |
| DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| DE69733169D1 (de) | Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs | |
| DE50103012D1 (de) | Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen | |
| ATE194076T1 (de) | Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen | |
| EP0286802A3 (de) | Verwendung von Ofloxacin zur lokalen Behandlung oder Prophylaxe von Beschwerden der Wurzelhaut der Zähne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |